NP Life Sciences Health Industry Group Inc. (ACAT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 60K 120K 180K FY22: 102K FY23: 164.6K FY22 FY23

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-21K -14K -7K 0 7K 14K 21K FY22: -18.9K FY23: -690 FY22 FY23

Net Income Annual

-21K -14K -7K 0 7K 14K 21K FY22: -18.9K FY23: -2.9K FY22 FY23

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-105K -70K -35K 0 35K 70K 105K FY22: 93.9K FY23: -73.6K FY22 FY23

Free Cash Flow Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Annual

0 15M 30M 45M FY22: 43M FY23: 43M FY22 FY23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: 0.00 Q3 '21: 0.00 Q4 '21: 0.00 Q1 '22: 0.00 Q2 '20 Q3 '20 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.